文献速递产科母胎医学

妊娠早期原发性巨细胞病毒感染应用超免疫球蛋白治疗的妊娠结局观察性研究

Outcome of pregnancies with recent primary cytomegalovirus infection in first trimester treated with hyperimmunoglobulin: observational study.
PubMed 文献 · Ultrasound Obstet Gynecol · 2021-03-17

该观察性研究纳入149例妊娠早期(≤14周)确诊近期原发性巨细胞病毒感染的孕妇,给予超免疫球蛋白(HIG)200 IU/kg母体体重静脉注射,每2周重复至约18周。主要结局为羊膜穿刺时的母胎传播率,结果显示6.5%(95%CI 3.2-11.7%)发生传播,抗IgM指数是唯一与传播显著相关的因素。

要点

  • 妊娠早期原发性CMV感染使用HIG治疗,母胎传播率为6.5%(95%CI 3.2-11.7%)。
  • 抗IgM指数是羊膜穿刺时母胎传播的唯一显著预测因素。
  • HIG治疗可能主要对妊娠早期或围受孕期的近期原发感染有益。

核心结论

  • HIG是预防妊娠期原发性CMV感染母胎传播的一种治疗选择。
  • HIG治疗似乎主要对妊娠早期或围受孕期近期原发感染且每2周200 IU/kg给药的孕妇有益。

研究设计与样本

  • 在德国图宾根、波恩、科隆和埃尔朗根大学医院产前医学部门以及斯图加特Gisela Enders教授实验室和图宾根大学医学病毒学研究所进行的持续性观察性研究。
  • 纳入标准为妊娠早期确诊近期原发性CMV感染且首次HIG给药时孕周≤14周,共纳入149例妊娠(153个胎儿)完成治疗。
  • HIG静脉给药剂量为200 IU/kg母体体重,每2周重复一次直至约18周妊娠。
  • 主要结局为羊膜穿刺时的母胎传播,采用多因素逻辑回归分析确定显著预测协变量。

主要发现

  • 孕妇中位年龄32.0岁,中位体重65.0 kg,首次转诊时中位孕周9.4周。
  • 中位抗CMV-IgG水平5.7 U/mL,抗CMV-IgM指数2.5,CMV-IgG亲和力22.3%。
  • HIG治疗开始中位孕周10.6周,结束中位孕周17.9周,每位患者平均给药4次。
  • 羊膜穿刺中位孕周20.4周,153例中143例(93.5%)胎儿未感染,10例(6.5%(95%CI,3.2-11.7%))发生母胎传播。
  • 单因素和多因素逻辑回归分析显示,抗IgM指数水平是唯一与羊膜穿刺时母胎传播显著相关的因素;但10例传播病例中仅4例(40.0%)抗IgM指数高于11.4(对应无传播妊娠的第95百分位)。

临床怎么用

  • 对于妊娠早期确诊近期原发性CMV感染的孕妇,可考虑使用HIG 200 IU/kg每2周一次直至约18周以预防母胎传播。
  • 抗IgM指数可作为预测母胎传播的参考指标,但大部分传播病例抗IgM指数并未显著升高,需综合评估。

局限性

  • 本研究为观察性研究,未设对照组,无法完全排除混杂因素。
  • 样本量有限,母胎传播病例数较少(10例),统计效能受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the efficacy of hyperimmunoglobulin (HIG) treatment in women with a recent primary cytomegalovirus (CMV) infection up to 14 weeks' gestation. METHODS: This is an ongoing observational study conducted at the prenatal medicine departments of the University Hospitals of Tübingen, Bonn, Cologne and Erlangen, Germany, as well as at the Laboratory Prof. Gisela Enders and Colleagues in Stuttgart, Germany and the Institute for Medical Virology at the University of Tübingen, Tübingen, Germany. Enrolment criteria were the presence of confirmed recent primary CMV infection in the first trimester and a gestational age at first HIG administration of ≤ 14 weeks. The following inclusion criteria indicated a recent primary infection: low anti-immunoglobulin (Ig)-G levels, low anti-CMV-IgG avidity in the presence of a positive CMV-IgM test and no positive reactivity or just seroconversion anti-gB2-IgG-reactivity. HIG administration was started as soon as possible within a few days after the first visit. HIG was administered intravenously at a dose of 200 IU/kg maternal body weight and repeated every 2 weeks until about 18 weeks' gestation. The primary outcome was maternal-fetal transmission at the time of amniocentesis. Multivariate logistic regression analysis was used to determine significant covariates that could predict maternal-fetal transmission. RESULTS: We included 149 pregnancies (153 fetuses) that completed the treatment. Median maternal age and weight were 32.0 years and 65.0 kg, respectively. Median gestational age at the time of first referral to one of the four centers was 9.4 weeks. Median anti-CMV-IgG level, anti-CMV-IgM index and CMV-IgG avidity were 5.7 U/mL, 2.5 and 22.3%, respectively. HIG treatment was started at a median gestational age of 10.6 weeks and ended at a median of 17.9 weeks. Within this time frame, HIG was administered on average four times in each patient. Amniocentesis was carried out at a median gestational age of 20.4 weeks. In 143 (93.5%) of the 153 cases, the fetus was not infected. Maternal-fetal transmission occurred in 10 cases (6.5% (95% CI, 3.2-11.7%)). On uni- and multivariate logistic regression analysis, the level of anti-IgM index was the only factor associated significantly with maternal-fetal transmission at amniocentesis. However, only four (40.0%) of the 10 cases with maternal-fetal transmission had an anti-IgM index above 11.4, which corresponds to the 95th centile of pregnancies without transmission. CONCLUSIONS: HIG is a treatment option to prevent maternal-fetal transmission in pregnancy with a primary CMV infection. However, HIG treatment seems to be beneficial primarily in women with a recent primary infection in the first trimester or during the periconceptional period, and when it is administered at a biweekly dose of 200 IU/kg. © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Kagan KO, Enders M, Hoopmann M, et al. Outcome of pregnancies with recent primary cytomegalovirus infection in first trimester treated with hyperimmunoglobulin: observational study. Ultrasound Obstet Gynecol. 2021. PMID: 33491819. doi:10.1002/uog.23596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。